Literature DB >> 8251871

Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: results from cross-sectional studies in 1988 and 1990.

L San1, M Torrens, C Castillo, M Porta, R de la Torre.   

Abstract

We assessed the prevalence of consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment in two cross-sectional studies conducted in 1988 (188 subjects) and in 1990 (197 subjects). Patients were enrolled in one of three different programmes: methadone maintenance programme (MMP), antagonist maintenance programme (AMP) and drug-free programme (DFP). Information given by participants was compared with results of urine screening for drugs. Urine samples were tested using enzyme immunoassay for the detection of heroin, cocaine, dextropropoxyphene, cannabis and benzodiazepines, and radioimmunoassay for buprenorphine. Sixty-six percent of patients in 1988 and 71% of patients in 1990 reported having consumed buprenorphine at some time during their history of drug dependence (period prevalence) and 5.9% and 6.1%, respectively, tested positive to the drug (point prevalence). In over 70% of these patients consumption was by the intravenous route. Consumption of cannabis, cocaine and benzodiazepines was also very high in the study population. Overall, patients in the DFP group consumed the largest number of the drugs tested, while those in the AMP group consumed the smallest number. Abuse of buprenorphine could be more widespread than previously reported.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251871     DOI: 10.1111/j.1360-0443.1993.tb02020.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  8 in total

1.  Impact of cannabis use during stabilization on methadone maintenance treatment.

Authors:  Jillian L Scavone; Robert C Sterling; Stephen P Weinstein; Elisabeth J Van Bockstaele
Journal:  Am J Addict       Date:  2013 Jul-Aug

2.  HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.

Authors:  R Lattanzi; L Negri; E Giannini; H Schmidhammer; J Schutz; G Improta
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 3.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Authors:  Michael A Yokell; Nickolas D Zaller; Traci C Green; Josiah D Rich
Journal:  Curr Drug Abuse Rev       Date:  2011-03

Review 5.  Polydrug abuse: a review of opioid and benzodiazepine combination use.

Authors:  Jermaine D Jones; Shanthi Mogali; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-08-02       Impact factor: 4.492

6.  Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user's perspective.

Authors:  Ali Ghaddar; Sanaa Khandaqji; Zeinab Abbass
Journal:  Subst Abuse Treat Prev Policy       Date:  2018-04-19

Review 7.  Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.

Authors:  Nikki Bozinoff; Vitor Tardelli; Dafna Sara Rubin-Kahana; Bernard Le Foll
Journal:  Harm Reduct J       Date:  2022-10-13

8.  Fifty Years of Research on Prenatal Substances: Lessons Learned for the Opioid Epidemic.

Authors:  Lynn T Singer; Christina Chambers; Claire Coles; Julie Kable
Journal:  Advers Resil Sci       Date:  2020-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.